Epitan raises $8 million in private placement
Wednesday, 11 August, 2004
EpiTan (ASX: EPT) has raised AUD$7.98 million via a private placement of 10.5 million fully paid ordinary with two European investors.
The shares were issued at AUD$0.76, a 6.4 per cent discount to the three-month volume weighted average price of AUD$0.91.
8.5 million shares were placed with FM Fund Management, run out of Zurich by hedge fund manager Florian Homm. Its Absolute Return Europe Fund is now a substantial shareholder in EpiTan, holding 6.8 per cent of the company’s shares.
A further 2 million shares were placed with UK biotech investment fund Mercury Investments.
Epitan also issued 6.6 million unlisted options exercisable over three years at AUD$1.03, which would provide it with a further AUD$6.87 in cash. EpiTan’s executive chairman and CEO, Dr Wayne Millen said the placement bought Epitan’s cash reserves to approximately AUD$13 million.
At time of writing shares in Epitan were trading at $0.87.
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
Archer completes potassium sensing alpha prototype
Quantum technology company Archer Materials Limited has developed an early Biochip prototype...
Farm animals and aquaculture cryopreservation partnership announced
Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...
